Butenafine HClCAS# 101827-46-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 101827-46-7 | SDF | Download SDF |
| PubChem ID | 443867 | Appearance | Powder |
| Formula | C23H28ClN | M.Wt | 353.93 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 25 mg/mL (70.64 mM; Need ultrasonic) H2O : 1 mg/mL (2.83 mM; Need ultrasonic) | ||
| Chemical Name | 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine;hydrochloride | ||
| SMILES | CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32.Cl | ||
| Standard InChIKey | LJBSAUIFGPSHCN-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C23H27N.ClH/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20;/h5-15H,16-17H2,1-4H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Butenafine HCl Dilution Calculator
Butenafine HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8254 mL | 14.1271 mL | 28.2542 mL | 56.5083 mL | 70.6354 mL |
| 5 mM | 0.5651 mL | 2.8254 mL | 5.6508 mL | 11.3017 mL | 14.1271 mL |
| 10 mM | 0.2825 mL | 1.4127 mL | 2.8254 mL | 5.6508 mL | 7.0635 mL |
| 50 mM | 0.0565 mL | 0.2825 mL | 0.5651 mL | 1.1302 mL | 1.4127 mL |
| 100 mM | 0.0283 mL | 0.1413 mL | 0.2825 mL | 0.5651 mL | 0.7064 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Butenafine hydrochloride is a synthetic benzylamine antifungal, works by inhibiting the synthesis of sterols by inhibiting squalene epoxidase.
- TG 100801 Hydrochloride
Catalog No.:BCC1997
CAS No.:1018069-81-2
- Desacetylmatricarin
Catalog No.:BCN7258
CAS No.:10180-88-8
- 7-O-Demethyl-3-isomangostin hydrate
Catalog No.:BCN7882
CAS No.:
- Elliotinol
Catalog No.:BCN5833
CAS No.:10178-31-1
- Boc-N-Me-Ser-OH
Catalog No.:BCC2613
CAS No.:101772-29-6
- PK 44 phosphate
Catalog No.:BCC2366
CAS No.:1017682-65-3
- LPA2 antagonist 1
Catalog No.:BCC5438
CAS No.:1017606-66-4
- Ladanein
Catalog No.:BCN6670
CAS No.:10176-71-3
- Nevadensin
Catalog No.:BCN6806
CAS No.:10176-66-6
- Jaceidin
Catalog No.:BCN5832
CAS No.:10173-01-0
- Sanggenofuran B
Catalog No.:BCN7194
CAS No.:1017277-40-5
- 6alpha,16,18-Trihydroxycleroda-3,13-dien-15,16-olide
Catalog No.:BCN1640
CAS No.:1017233-48-5
- Diclazuril
Catalog No.:BCC8937
CAS No.:101831-37-2
- 7-Z-Trifostigmanoside I
Catalog No.:BCN7869
CAS No.:1018898-17-3
- LX-4211
Catalog No.:BCC1714
CAS No.:1018899-04-1
- sodium 4-pentynoate
Catalog No.:BCC1958
CAS No.:101917-30-0
- Dabigatran etexilate benzenesulfonate
Catalog No.:BCC8925
CAS No.:1019206-65-5
- Regorafenib monohydrate
Catalog No.:BCC1884
CAS No.:1019206-88-2
- Calyculin A
Catalog No.:BCC2457
CAS No.:101932-71-2
- S0859
Catalog No.:BCC1914
CAS No.:1019331-10-2
- Octacosyl (E)-ferulate
Catalog No.:BCN5834
CAS No.:101959-37-9
- Zardaverine
Catalog No.:BCC2069
CAS No.:101975-10-4
- GW791343 dihydrochloride
Catalog No.:BCC1613
CAS No.:1019779-04-4
- Acetoacetanilide
Catalog No.:BCC8803
CAS No.:102-01-2
Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria.[Pubmed:12895182]
Int J Dermatol. 2003 Sep;42 Suppl 1:11-7.
BACKGROUND: In many instances, a cutaneous fungal infection may exist concomitantly with bacterial involvement. In this study we compared the in vitro activity of three antifungal agents against the dermatophytes, yeasts and bacteria recovered most commonly from cutaneous mycoses and bacterial infections. METHODS: Using a microdilution method adapted from the National Committee for Clinical Laboratory Standards (NCCLS), we determined the minimum inhibitory concentrations (MICs) of ciclopirox olamine, econazole nitrate and Butenafine HCl against a panel of dermatophyte fungi and yeasts (n = 39) and bacterial isolates (n = 45). RESULTS: All three antifungals demonstrated comparable activity against the dermatophytes tested, with a MIC range of 0.03-0.25 micro g/ml for ciclopirox, < 0.001-0.25 micro g/ml for econazole and 0.03-0.25 micro g/ml for butenafine. For yeasts, ciclopirox showed activity against all isolates, with an MIC range of 0.001-0.25 micro g/ml, whereas econazole had a broader range of 0.125-> 0.5 micro g/ml. Butenafine displayed limited activity against the yeast Candida albicans and no activity against Malassezia furfur. For the antibacterial activity studies, ciclopirox demonstrated activity against all isolates tested with a range of 0.06-2 micro g/ml, while econazole showed activity against Gram-positive bacteria only, with a MIC range of 0.004-0.25 micro g/ml. Butenafine HCl had a limited activity against bacterial isolates tested, showing activity against beta-hemolytic Streptococcus Group A and Corynebacterium only. Neither econazole nitrate nor Butenafine HCl demonstrated activity against any of the Gram-negative strains evaluated in this study. CONCLUSIONS: The data suggest that ciclopirox olamine has the broadest in vitro activity, in comparison to econazole and Butenafine HCl, against bacteria, yeasts and bacteria. These findings may have implications in the use of these antimycotics in the treatment of mixed cutaneous infections where bacteria or yeasts are present in addition to dermatophytes.
